
Jim Sullivan, Vanqua Bio CEO
Spurred on by OrbiMed partner's diagnosis, Vanqua Bio takes aim at neurodegenerative disease with blue-chip backers
The FDA’s recent approval of Biogen’s Aduhelm has provided a spark plug for neuroscience research across the biopharma spectrum with investors more likely than ever …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.